Medical Innovation Exchange

Soligenix's stock sinks 38% after FDA refuses to consider lymphoma therapy application

https://www.fiercebiotech.com/biotech/soligenxs-stock-sinks-36-after-fda-refuses-consider-lymphoma-therapy-application

Leave a Comment

Your email address will not be published. Required fields are marked *

Leave the field below empty!